MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


IN BRIEF: GSK highlights positive results from Nucala trial

ALN

GSK PLC - London-based pharmaceutical maker - Says trial of Nucala, whose generic name is mepolizumab, shows positive results in the treatment of chronic obstructive pulmonary disease. The results shows a 21% reduction in the annualised rate of moderate-to-severe exacerbations in a wide COPD population. The study assesses mepolizumab, a monoclonal antibody that targets interleukin-5, in a variety of COPD patients. Nucala is not yet approved for the treatment of COPD in any country, but regulatory submissions are under review in several countries, GSK says, including the US, China and the EU.

Current stock price: 1,482.51 pence

12-month change: down 13%

Copyright 2025 Alliance News Ltd. All Rights Reserved.